Our work speaks for itself.
Robust and reproducible data for the overall health of cells exposed to a new drug is essential. Whether it is to test the toxicity of a drug on healthy cells or cancer-killing capacity of a novel cancer drug, we will screen apoptotic and necrotic markers in real-time up to 72 hours after treatment.
We will also assist with the important understanding of the underlying mechanism of action.
Apoptosis, Necrosis, and Viability of colon cancer cells in response to immunotherapy
Phosphorylation of Akt in cancer cells, in response to immunotherapy
Intracellular signaling cascade (ERK-pathway) inhibited by the MEK-inhibitor Trametinib in cancer cells. The phosphorylation of ERK is diminished in the cancer cell with increasing concentration of the drug.